普拉克索增强治疗难治性单极抑郁症急性期：英国一项安慰剂对照、双盲、随机试验

IF 30.8 1区医学 Q1 PSYCHIATRY

Lancet Psychiatry Pub Date : 2025-06-29 DOI:10.1016/s2215-0366(25)00194-4

Prof Michael Browning DPhil, Prof Philip J Cowen MD, Ushma Galal MSc, Prof Ashley Baldwin MD, Prof Anthony J Cleare MD, Jonathan Evans MD, Prof Quentin J M Huys MD, Prof David Kessler MD, Micheal Kurkar MD, Neil Nixon MD, Abhinav Rastogi FRCPsych, Stuart Watson MD, Prof Ly-Mee Yu DPhil, Sam Mort PGCert, Prof Judit Simon DPhil, Agata Laszewska PhD, Alexander C Lewis BSc, Sophie M Roberts BSc, Victoria Fiske MBChB, Lisa M Frending MSc, Catherine Money BSc, Beata R Godlewska MD, Howard T Ryland MD, Don Chamith Halahakoon MBChB, Laurence Astill Wright MBChB, Barbara Salas MBBS, Apoorva Peddada MBBS, Mourad Wahba MRCPsych, Katharine S Taylor MBBS, Jess Kerr-Gaffney PhD, Duncan Swiffen MD, Caroline Zangani MD, Katharine A Smith MD, Prof Catherine J Harmer DPhil, Prof John R Geddes MD, PAX-D study group

{"title":"普拉克索增强治疗难治性单极抑郁症急性期：英国一项安慰剂对照、双盲、随机试验","authors":"Prof Michael Browning DPhil, Prof Philip J Cowen MD, Ushma Galal MSc, Prof Ashley Baldwin MD, Prof Anthony J Cleare MD, Jonathan Evans MD, Prof Quentin J M Huys MD, Prof David Kessler MD, Micheal Kurkar MD, Neil Nixon MD, Abhinav Rastogi FRCPsych, Stuart Watson MD, Prof Ly-Mee Yu DPhil, Sam Mort PGCert, Prof Judit Simon DPhil, Agata Laszewska PhD, Alexander C Lewis BSc, Sophie M Roberts BSc, Victoria Fiske MBChB, Lisa M Frending MSc, Catherine Money BSc, Beata R Godlewska MD, Howard T Ryland MD, Don Chamith Halahakoon MBChB, Laurence Astill Wright MBChB, Barbara Salas MBBS, Apoorva Peddada MBBS, Mourad Wahba MRCPsych, Katharine S Taylor MBBS, Jess Kerr-Gaffney PhD, Duncan Swiffen MD, Caroline Zangani MD, Katharine A Smith MD, Prof Catherine J Harmer DPhil, Prof John R Geddes MD, PAX-D study group","doi":"10.1016/s2215-0366(25)00194-4","DOIUrl":null,"url":null,"abstract":"About 30% of patients with depression treated with antidepressant medication do not respond sufficiently to the first agents used. Pramipexole might usefully augment antidepressant medication in such cases of treatment-resistant depression, but data on its effects and tolerability are scarce. We aimed to assess the efficacy and tolerability of pramipexole augmentation of ongoing antidepressant treatment, over 48 weeks, in patients with treatment-resistant depression.","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"4648 2 1","pages":""},"PeriodicalIF":30.8000,"publicationDate":"2025-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UK\",\"authors\":\"Prof Michael Browning DPhil, Prof Philip J Cowen MD, Ushma Galal MSc, Prof Ashley Baldwin MD, Prof Anthony J Cleare MD, Jonathan Evans MD, Prof Quentin J M Huys MD, Prof David Kessler MD, Micheal Kurkar MD, Neil Nixon MD, Abhinav Rastogi FRCPsych, Stuart Watson MD, Prof Ly-Mee Yu DPhil, Sam Mort PGCert, Prof Judit Simon DPhil, Agata Laszewska PhD, Alexander C Lewis BSc, Sophie M Roberts BSc, Victoria Fiske MBChB, Lisa M Frending MSc, Catherine Money BSc, Beata R Godlewska MD, Howard T Ryland MD, Don Chamith Halahakoon MBChB, Laurence Astill Wright MBChB, Barbara Salas MBBS, Apoorva Peddada MBBS, Mourad Wahba MRCPsych, Katharine S Taylor MBBS, Jess Kerr-Gaffney PhD, Duncan Swiffen MD, Caroline Zangani MD, Katharine A Smith MD, Prof Catherine J Harmer DPhil, Prof John R Geddes MD, PAX-D study group\",\"doi\":\"10.1016/s2215-0366(25)00194-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"About 30% of patients with depression treated with antidepressant medication do not respond sufficiently to the first agents used. Pramipexole might usefully augment antidepressant medication in such cases of treatment-resistant depression, but data on its effects and tolerability are scarce. We aimed to assess the efficacy and tolerability of pramipexole augmentation of ongoing antidepressant treatment, over 48 weeks, in patients with treatment-resistant depression.\",\"PeriodicalId\":48784,\"journal\":{\"name\":\"Lancet Psychiatry\",\"volume\":\"4648 2 1\",\"pages\":\"\"},\"PeriodicalIF\":30.8000,\"publicationDate\":\"2025-06-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/s2215-0366(25)00194-4\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2215-0366(25)00194-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

摘要

大约30%接受抗抑郁药物治疗的抑郁症患者对最初使用的药物没有充分的反应。在这种难治性抑郁症的病例中，普拉克索可能会有效地增加抗抑郁药物，但关于其效果和耐受性的数据很少。我们的目的是评估在治疗难治性抑郁症患者持续48周的抗抑郁药物治疗中增加普拉克索的疗效和耐受性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UK

About 30% of patients with depression treated with antidepressant medication do not respond sufficiently to the first agents used. Pramipexole might usefully augment antidepressant medication in such cases of treatment-resistant depression, but data on its effects and tolerability are scarce. We aimed to assess the efficacy and tolerability of pramipexole augmentation of ongoing antidepressant treatment, over 48 weeks, in patients with treatment-resistant depression.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Lancet Psychiatry PSYCHIATRY-

CiteScore

58.30

自引率

0.90%

发文量

期刊介绍： The Lancet Psychiatry is a globally renowned and trusted resource for groundbreaking research in the field of psychiatry. We specialize in publishing original studies that contribute to transforming and shedding light on important aspects of psychiatric practice. Our comprehensive coverage extends to diverse topics including psychopharmacology, psychotherapy, and psychosocial approaches that address psychiatric disorders throughout the lifespan. We aim to channel innovative treatments and examine the biological research that forms the foundation of such advancements. Our journal also explores novel service delivery methods and promotes fresh perspectives on mental illness, emphasizing the significant contributions of social psychiatry.